- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| So | Upstream Bio presents additional Phase 2 data for verekitug | 4 | Investing.com | ||
| UPSTREAM BIO Aktie jetzt für 0€ handeln | |||||
| So | Upstream Bio: Positive Phase-2-Daten für Verekitug, Aktie dennoch unter Druck | 1 | Investing.com Deutsch | ||
| So | Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting | 2 | GlobeNewswire (USA) | ||
| Do | Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 | 2 | GlobeNewswire (USA) | ||
| 13.02. | Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns | 20 | Benzinga.com | ||
| 11.02. | Upstream Bio Shares Plunge 52% Despite Positive Phase 2 Asthma Data | 5 | RTTNews | ||
| 11.02. | Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts | 1 | Benzinga.com | ||
| 11.02. | Upstream Bio-Aktie stürzt nach gemischten Ergebnissen der Phase-2-Asthmastudie ab | 2 | Investing.com Deutsch | ||
| 11.02. | Upstream Bio down despite mid-stage trial win for asthma drug | 1 | Seeking Alpha | ||
| 11.02. | Upstream Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.02. | Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma | 185 | GlobeNewswire (Europe) | - Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing - - Verekitug also delivered... ► Artikel lesen | |
| 11.02. | Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma | 1 | GlobeNewswire (USA) | ||
| 17.12.25 | Mizuho initiates Upstream Bio stock with Outperform rating on asthma drug potential | 4 | Investing.com | ||
| 17.12.25 | Upstream Bio: Mizuho startet Coverage mit "Outperform" dank Potenzial bei Asthma-Medikament | 1 | Investing.com Deutsch | ||
| 05.11.25 | Upstream Bio, Inc. reports Q3 results | 2 | Seeking Alpha | ||
| 05.11.25 | Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress | 262 | GlobeNewswire (Europe) | - Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary... ► Artikel lesen | |
| 05.11.25 | Upstream Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11.25 | Upstream Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.10.25 | Piper Sandler reiterates Overweight rating on Upstream Bio stock | 3 | Investing.com | ||
| 14.10.25 | Truist Securities initiates Upstream Bio stock with Buy rating on respiratory drug potential | 2 | Investing.com |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,960 | +1,38 % | flatexDEGIRO, Qiagen, Börse München - 4investors-Weekend | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Und welche Titel haben besonders starke Kursbewegungen verzeichnet? Vor allem für Trader ist es wichtig zu wissen... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 62,98 | -2,63 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights | Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS... ► Artikel lesen | |
| ARCELLX | 113,80 | -0,05 % | Aktien New York Ausblick: Leichte Verluste nach Trumps Zollankündigung | NEW YORK (dpa-AFX) - Die US-Börsen steuern am Montag vor dem Hintergrund neuer Zollunsicherheit auf einen etwas tieferen Handelsauftakt zu. Nachdem der Oberste Gerichtshof der USA dem Präsidenten Donald... ► Artikel lesen | |
| EVOTEC | 5,880 | +0,38 % | Evotec Aktie: Kann man "diesem Braten wirklich trauen"? | © Foto: Julia Koblitz auf Unsplash (Symbolbild)Neue Aufträge, ein Sparprogramm und frische Analystenkommentare. Die Evotec-Aktie sendet wieder Lebenszeichen. Doch wer die Geschichte dieses Hamburger... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 14,750 | -79,74 % | Novartis Pharma AG: Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy | Adds Avidity's differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks multi-billion-dollar... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,100 | -2,26 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| CARDIO DIAGNOSTICS | 6,490 | +24,33 % | Cardio Diagnostics Holdings, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 15,580 | +2,70 % | ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance | ||
| RELAY THERAPEUTICS | 10,250 | +12,02 % | Relay Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| PRAXIS PRECISION MEDICINES | 336,75 | -1,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,820 | -3,48 % | Vera Therapeutics, Inc. - 10-K, Annual Report | ||
| KYMERA THERAPEUTICS | 91,36 | -3,85 % | Morgan Stanley cuts Kymera Therapeutics stock price target on pipeline progress | ||
| COGENT BIOSCIENCES | 38,870 | -1,55 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | ||
| EDGEWISE THERAPEUTICS | 30,450 | +2,77 % | Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs | - CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026 -
- Phase 1 healthy adult trial... ► Artikel lesen | |
| PRIME MEDICINE | 4,630 | +5,71 % | Prime Medicine, Inc.: Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates | -- New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as... ► Artikel lesen |
Das Unternehmen UPSTREAM BIO INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,210 (-2,66 %) liegt der Kurs bei 7,670 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu UPSTREAM BIO INC finden Sie auf Wallstreet Online.